Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 in Autoimmune Hepatitis
NCT03217422Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2018
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of ianalumab in autoimmune hepatitis (AIH), sponsored by Novartis. Started Feb 2018; status: completed.
02
Drugs
ianalumab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on NCT03217422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217422.